Search the Newsreel

CNH Industrial Posts Upbeat Q2 Earnings, Joins Autolus Therapeutics, Bowhead Specialty Holdings And Other Big Stocks Moving Higher On Monday

CNH Industrial (NYSE: CNH) shares surged after reporting better-than-expected Q2 earnings and raising its FY26 adjusted EPS guidance. Several other stocks, including Atkore Inc (NYSE: ATKR), Autolus Therapeutics PLC (NASDAQ: AUTL), and Newell Brands Inc (NASDAQ: NWL), also saw significant gains following positive financial …

Equities Analysts Offer Predictions for AUTL Q3 Earnings

HC Wainwright raised its Q3 2026 EPS estimate for Autolus Therapeutics (NASDAQ:AUTL) to a loss of $0.20 per share from $0.21, maintaining a "Buy" rating and a $10 price target. Autolus Therapeutics reported a Q2 loss of $0.15 per share, beating expectations of $0.21, …

Autolus Q2 Net Loss Narrows As AUCATZYL Sales Surge 119%; CARLYSLE Data Expected By Year-End

(RTTNews) - Autolus Therapeutics plc (AUTL), a commercial-stage biopharmaceutical company, announced financial results for the second quarter reflecting approximately 119% revenue growth from AUCATZYL product sales and a narrower net loss. Autolus Therapeutics develops T cell therapies and candidates for the treatment of cancer …

Autolus Therapeutics plc 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:AUTL) 2026-08-11

* Autolus Therapeutics (AUTL [https://seekingalpha.com/symbol/AUTL]) is scheduled to announce Q2 earnings results on Tuesday, August 11th, before market open. * The consensus EPS Estimate is -$0.19 [https://seekingalpha.com/symbol/AUTL/earnings/estimates] (-5.6% Y/Y) and the consensus Revenue Estimate is $40.15M (+92.1% Y/Y). * Over the last 1 year, …

Autolus Raises Year-End Outlook as Aucatzyl Sales Accelerate

Autolus' revenue from its CAR T-cell therapy Aucatzyl more than doubled in Q2 2026 compared to Q2 2025, reaching $45.7 million, leading the company to raise its full-year product revenue guidance to between $140 million and $150 million. The company is focusing on expanding …

Autolus Therapeutics (NASDAQ:AUTL) Releases Earnings Results, Beats Estimates By $0.06 EPS

Autolus shares rise as Q2 beat and higher AUCATZYL guidance signal launch momentum

Autolus Therapeutics plc reported better-than-expected Q2 results with a narrower loss per share and significantly higher revenue, exceeding analyst estimates. The company raised its full-year 2026 revenue guidance for AUCATZYL, indicating strong launch momentum driven by physician enthusiasm and expanding use. Improvements in gross …

Autolus Therapeutics (NASDAQ:AUTL) Trading 13.3% Higher Following Strong Earnings

Autolus Therapeutics (NASDAQ:AUTL) saw its shares rise by 13.3% after reporting stronger-than-expected quarterly earnings. The company posted a negative EPS of $0.15, beating estimates by $0.06, and revenue of $45.69 million, exceeding the $38.56 million forecast. Analyst sentiment remains largely positive, with a "Moderate …

Autolus Therapeutics PLC reports results for the quarter ended June 30 - Earnings Summary

Autolus Therapeutics PLC has released its earnings summary for the quarter that concluded on June 30. The article, sourced from Reuters and accessible through TradingView, provides a concise overview of the company's financial performance during this period. Readers can access the full report for …

Autolus Therapeutics' AUCATZYL Q2 Revenue Surges 119%; Boosts FY26 Outlook

(RTTNews) - Autolus Therapeutics plc (AUTL), a commercial-stage biopharmaceutical company, has announced its operational and financial results for the second quarter ended June 30, 2026. The company's marketed therapy, AUCATZYL (obecabtagene autoleucel; obe-cel), is a CD19-directed CAR-T therapy approved for adults with relapsed or …

Autolus Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates

Autolus Therapeutics reported significant financial and operational progress in Q2 2026, with AUCATZYL® net product revenue reaching $45.7 million, a 119% year-over-year increase, and full-year guidance raised to $140-$150 million. The company also strengthened its capital base with a $250 million credit facility and …

Autolus shares rise 3% on Q2 beat, raised revenue guidance

Autolus Therapeutics (NASDAQ:AUTL) reported a Q2 beat, with shares rising 3.19% pre-market. The company exceeded analyst expectations with a loss of -$0.15 per share and revenue of $45.7 million, a 119% increase YoY. Autolus also raised its full-year 2026 net product revenue guidance for …

Autolus Therapeutics (AUTL) Earnings Date and Reports 2026 $AUTL

Autolus Therapeutics Q2 2026 Earnings Preview

* Autolus Therapeutics (AUTL [https://seekingalpha.com/symbol/AUTL]) is scheduled to announce Q2 earnings results on Tuesday, August 11th, before market open. * The consensus EPS Estimate is -$0.19 [https://seekingalpha.com/symbol/AUTL/earnings/estimates] (-5.6% Y/Y) and the consensus Revenue Estimate is $40.15M (+92.1% Y/Y). * Over the last 1 year, …

Renaissance Technologies LLC Has $3.17 Million Position in Autolus Therapeutics PLC Sponsored ADR $AUTL

Renaissance Technologies LLC reduced its stake in Autolus Therapeutics PLC (NASDAQ:AUTL) by 26% in the first quarter, selling 805,905 shares but retaining 2.30 million shares valued at approximately $3.17 million. Institutional investors collectively own 72.83% of the company. Autolus Therapeutics maintains a "Moderate Buy" …

Autolus Therapeutics plc (AUTL) Stock Analysis: Biotechnology Innovator with 333% Potential Upside

Autolus Therapeutics (AUTL) is a clinical-stage biopharmaceutical company focusing on T cell therapies for cancer and autoimmune diseases, showing a potential upside of 333.75%. Despite operating at a loss, the company has a robust pipeline, strong analyst buy ratings with an average target price …

Autolus Raises AUCATZYL Outlook, Secures New Credit Facility

Autolus Therapeutics has raised its full-year 2026 guidance for AUCATZYL net product revenue to $140 million to $150 million, following strong second-quarter sales and improved operational efficiencies. The company also secured a five-year, interest-only senior credit facility of up to $250 million with Perceptive …

Latham & Watkins Advises Perceptive Advisors on Growth Financing for Leading Oncology Biotech Autolus Therapeutics

Latham & Watkins LLP advised Perceptive Advisors on a senior secured notes facility of up to US$250 million for Autolus Therapeutics plc. The financing includes an initial US$75 million, with additional funds available based on Autolus's options and revenue milestones. This funding, combined with …

Autolus Therapeutics (AUTL) Projected to Release Quarterly Earnings on Tuesday

Press Release: Autolus Therapeutics Reports Preliminary Second Quarter 2026 Net Product Revenue and Announces Credit Facility of up to $250 Million With Perceptive Advisors

Autolus Therapeutics announced preliminary second quarter 2026 net product revenue and secured a credit facility of up to $250 million with Perceptive Advisors. This financial arrangement is expected to support the company's operational growth and strategic initiatives. The report indicates a positive financial outlook …

Autolus Sets Aug. 11 Webcast for Q2 Results and Business Update

Autolus Therapeutics (Nasdaq: AUTL) will release its second-quarter 2026 financial results and operational highlights before the U.S. market opens on Tuesday, August 11, 2026. The company will also host a conference call and webcast at 8:30 AM EDT / 1:30 PM BST to discuss …

Autolus Therapeutics to Report Second Quarter 2026 Financial Results and Host Conference Call on August 11, 2026

Autolus Therapeutics plc (Nasdaq: AUTL) announced it will release its second quarter 2026 financial results and operational highlights before the open of U.S. markets on Tuesday, August 11, 2026. Management will host a conference call and webcast at 8:30 am EDT / 1:30 pm …

Autolus raises sales guidance, secures $75M credit facility

Autolus Therapeutics plc announced preliminary Q2 2026 net product revenue of approximately $45 million for AUCATZYL and raised its full-year sales guidance to $140-$150 million. The company also secured a credit facility of up to $250 million with Perceptive Advisors, receiving an initial $75 …

Autolus Secures $250 Million Notes Facility From Perceptive, Issues Warrants and Registration Rights

Autolus Therapeutics has secured a senior secured notes facility worth up to $250 million from Perceptive, with an initial draw of $75 million. The agreement includes the issuance of warrants for up to 3.5 million ADSs to Perceptive and grants registration rights for their …

Autolus Therapeutics (NASDAQ:AUTL) Shares Gap Up - Still a Buy?

Autolus Therapeutics PLC (AUTL) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Autolus Therapeutics PLC (AUTL), highlighting its current risk score of 3.55, which ranks it 128 out of 384 in the Biotechnology & Medical Research industry. The assessment details the stock's beta of 1.98, indicating higher volatility compared …

Autolus Therapeutics PLC (AUTL) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Autolus Therapeutics PLC (AUTL), highlighting its current valuation score and P/E ratio. The company's valuation score is 7.88, ranking 173 out of 385 in the Biotechnology & Medical Research industry. Its P/E ratio is -1.34, which is …

Autolus Therapeutics PLC (AUTL) Institutional Confidence

Autolus Therapeutics PLC (AUTL) has an institutional shareholding score of 7.00, placing it 80th out of 386 in its industry, with institutional holdings making up 78.88% of shares. This proportion shows a 12.89% decrease quarter-over-quarter. James Simons is noted as the largest individual institutional …

Autolus Therapeutics PLC (AUTL) Income Statement

This article provides the quarterly and annual income statements for Autolus Therapeutics PLC (AUTL), offering detailed financial data from FY2019Q1 to FY2026Q1. It includes metrics such as total revenue, cost of revenue, operating expenses, net income, and earnings per share. The piece aims to …

AUTL|Autolus Therapeutics PLC|Price:1.450|Chg%:-0.070

Autolus Therapeutics PLC (AUTL) shows solid fundamentals and high growth potential, yet its stock performance has been weak recently. The company develops T-cell therapies for cancer and autoimmune diseases, with an approved commercial product, AUCATZYL. Despite being considered fairly valued by TradingKey and receiving …

Autolus Therapeutics PLC (AUTL) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Autolus Therapeutics PLC (AUTL) regarding its dividend and stock split history. It states that the company has distributed $0.00 in dividends over the past five years, indicating no recent dividend payouts. The article primarily functions as a data …

Autolus Therapeutics PLC (AUTL) Cash Flow Statement

This article provides a detailed quarterly and annual cash flow statement for Autolus Therapeutics PLC (AUTL), covering operating, investing, and financing activities. It presents comprehensive financial data from Q1 2019 through Q1 2026, alongside explanations of key cash flow metrics like operating cash flow, …

Autolus Therapeutics plc Revenue Breakdown – NASDAQ:AUTL

Autolus Therapeutics plc (NASDAQ: AUTL) generated 75.39 million USD in revenue last year, primarily from its Chimeric Antigen Receptors T Cell Therapies segment. The United States was the largest contributor to its revenue, accounting for 75.34 million USD. This represents a significant increase from …